| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from rat) |
| Target | CD2 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Siplizumab (MEDI-507) is an investigational monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and has been tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.[1][2][3][4][5]
- ^ Podestà, Manuel A.; Binder, Christian; Sellberg, Felix; DeWolf, Susan; Shonts, Brittany; Ho, Siu-Hong; Obradovic, Aleksandar; Waffarn, Elizabeth; Danzl, Nichole; Berglund, David; Sykes, Megan (January 2020). "Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro". American Journal of Transplantation. 20 (1): 88–100. doi:10.1111/ajt.15533. PMC 6940533. PMID 31319439.
- ^ Langley, Richard G.; Papp, Kim; Bissonnette, Robert; Toth, Darryl; Matheson, Robert; Hultquist, Micki; White, Barbara (July 2010). "Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies". International Journal of Dermatology. 49 (7): 818–828. doi:10.1111/j.1365-4632.2010.04512.x. PMID 20618506. S2CID 21145758.
- ^ O'Mahony, Deirdre; Morris, John C.; Stetler-Stevenson, Maryalice; Matthews, Helen; Brown, Margaret R.; Fleisher, Thomas; Pittaluga, Stefania; Raffeld, Mark; Albert, Paul S.; Reitsma, Dirk; Kaucic, Karen; Hammershaimb, Luz; Waldmann, Thomas A.; Janik, John E. (1 April 2009). "EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies". Clinical Cancer Research. 15 (7): 2514–2522. doi:10.1158/1078-0432.CCR-08-1254. PMC 7322623. PMID 19293260.
- ^ Adkins, Douglas; Ratanatharathorn, Voravit; Yang, Harry; White, Barbara (27 July 2009). "Safety Profile and Clinical Outcomes in a Phase I, Placebo-Controlled Study of Siplizumab in Acute Graft-Versus-Host Disease". Transplantation. 88 (2): 198–202. doi:10.1097/TP.0b013e3181abfbf7. PMID 19623014.
- ^ Cvetkovski, Filip; Razavi, Ronia; Sellberg, Felix; Berglund, Erik; Berglund, David (October 2023). "Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro". American Journal of Transplantation. 23 (10): 1603–1611. doi:10.1016/j.ajt.2023.05.032. PMID 37270108.